CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas By Ogkologos - July 16, 2026 208 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 10-year follow-up of a phase II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up August 5, 2025 FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC February 2, 2023 Metastatic Breast Cancer: ESMO Living Guideline August 24, 2026 How I’m Working to Erase the Stigma of Lung Cancer: A... November 22, 2023 Load more HOT NEWS ESMO Welcomes the WHO Global Status Report on Cancer with Key... Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan Honoring Other’s Wishes
